Biosynchronous transdermal drug delivery

1. A method for delivering an active substance to a user, the method comprising:

placing a delivery device in contact with the user's skin, the dispensing device comprising a reservoir, a skin interface, a programmable dosage controller configured to control the time and dosage of the active substance according to a dosage profile corresponding to a circadian rhythm of the user, and a solvent recovery element;

dispensing a first portion of the active substance and solvent from the reservoir to the skin interlace according to the dosage profile;

delivering the active substance through the skin interface to the skin; and

removing a portion of the solvent from the skin interface and trapping the solvent within the solvent recovery element to control active substance delivery according to the dosage profile.

2. The method of claim 1 , wherein the skin interlace comprises a highly permeable membrane.

3. The method of claim 2 , further comprising diffusing the active substance across a surface, area of the highly permeable membrane.

4. The method of claim 3 , wherein delivering the active substance through the skin interface includes delivering the active substance across a surface area of the highly permeable membrane to the skin.

5. The method of claim 1 , wherein the programmable dosage controller is configured to control a valve in fluid communication with the reservoir.

6. The method of claim 1 , wherein the delivery device is adhesively attached to the skin.

7. The method of claim 1 , wherein the programmable dosage controller comprises timing routines corresponding to the circadian rhythm.

8. The method of claim 7 , wherein the timing routines are selected to deliver the active substance at a time, rate, sequence and/or cycle corresponding to the circadian rhythm.

9. The method of claim 1 , wherein the active substance comprises nicotine and the dosage profile is configured to deliver the nicotine at times that are associated with nicotine cravings.

10. The method of claim 9 , wherein at least one of the times corresponds to a time at which the user experiences a morning nicotine craving.

11. The method of claim 1 , Further comprising: removing the delivery device after contacting the skin for greater than 24 hours.

12. The method of claim 1 , further comprising: removing the delivery device after contacting the skin for greater than 72 hours.

13. The method of claim 1 , wherein the reservoir contains the active substance and solvent.

14. The method of claim 13 , further comprising: replacing the reservoir with a second reservoir containing an active substance and a solvent.

15. The method of claim 14 , further comprising: using the delivery device with the second reservoir for greater than 72 hours.

16. The method of claim 1 , wherein the solvent recovery element is a waste reservoir.

17. The method of claim 1 , wherein the active substance comprises a stimulant and the dosage profile is configured to deliver the stimulant during a 1-2 hour pre-wake-up period.

18. The method of claim 1 , wherein the active substance comprises cold medicine and the dosage profile is configured to deliver the cold medicine while the user sleeps.

19. The method of claim 18 , further comprising dispensing vitamins and/or minerals to the skin interface while the user sleeps.

20. The method of claim 1 , wherein the active substance comprises nitroglycerine and the dosage profile is configured to deliver the nitroglycerine while the user sleeps in first amount in a first time period and in a second amount higher than the first amount in a second time period.

21. The method of claim 1 , wherein the active substance is an asthma drug and the dosage profile is configured to deliver the asthma drug while the user sleeps.

22. The method of claim 1 , wherein the active substance is a hypertension drug and the dosage profile is configured to deliver the hypertension drug while the user sleeps.

23. The method of claim 1 , wherein the active substance is selegiline and the dosage profile is configured to deliver the selegiline while the user sleeps.

24. A method for delivering an active substance to a user, the method comprising:

placing a delivery device in contact with the user's skin, the dispensing device comprising a reservoir, a skin interface, a programmable dosage controller configured to control the time and dosage of the active substance according to a dosage profile and a solvent recovery element;

dispensing a first portion of the active substance and solvent from the reservoir to the skin interface according to the dosage profile;

removing a portion of the solvent from the skin interface into the solvent recovery element to control active substance concentration and to control active substance delivery according to the dosage profile; and

delivering the active substance through the skin interface to the skin in discreet doses over a 24 hour period to ensure consistent bioavailability.

25. A method for delivering an active substance and to a user, the method comprising:

placing a delivery device in contact with the user's skin, the dispensing device comprising a reservoir, a skin interface, a programmable dosage controller configured to control the time and dosage of the active substance according to a dosage profile and a solvent recovery element;

dispensing a first portion of the active substance and solvent from the reservoir to the skin interface according to the dosage profile;

removing a portion of the solvent from the skin interface into the solvent recovery element to control active substance concentration and to control active substance delivery according to the dosage profile; and

delivering the active substance through the skin interface to the skin in greater amounts upon wake up and at meal times to assist with weight loss.